NEW YORK / Apr 13, 2023 / Business Wire / Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, will release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023.
Management will review these results in a conference call beginning at 5:00 PM (ET). The call-in number and webcast link are as follows:
● Live Call: (877) 400-4403
● Conference ID: 6577079
The call will be archived and available on Oscar’s investor relations website (www.ir.hioscar.com) following May 9, 2023.
About Oscar Health
Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the health care system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of over one million members as of January 31, 2023. We offer Individual & Family, Small Group and Medicare Advantage plans, and +Oscar, our full stack technology platform. Our vision is to refactor health care to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.
For more information, please visit www.hioscar.com.
| Last Trade: | US$20.51 |
| Daily Change: | -0.16 -0.77 |
| Daily Volume: | 11,199,893 |
| Market Cap: | US$4.570B |
September 15, 2025 August 06, 2025 July 22, 2025 May 07, 2025 February 04, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
